EcoDrugPlus

5-Hydroxytryptamine Receptor 3d

Ensembl ID : ENSPVAG00000012023
Gene Symbol: HTR3D
1 Cross references
57 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSPVAG00000006368
Gene Symbol: HTR4
1 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSPVAG00000000381
Gene Symbol: HTR5A
1 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSPVAG00000009240
Gene Symbol: HTR6
1 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSPVAG00000010518
Gene Symbol: HTR7
1 Cross references
219 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPVAG00000005301
Gene Symbol: ARAF
1 Cross references
190 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPVAG00000001515
Gene Symbol: ABL1
1 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSPVAG00000005332
Gene Symbol: ADAM17
1 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSPVAG00000014340
Gene Symbol: ADAMTS5
1 Cross references
200 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSPVAG00000003536
Gene Symbol: ADRM1
1 Cross references
255 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSPVAG00000015685
Gene Symbol: AKT1
1 Cross references
213 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSPVAG00000011760
Gene Symbol: AKT2
1 Cross references
253 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).